Drugmaker opts for spinoff over sale

Pharmaceutical giant GlaxoSmithKline recently rejected a takeover offer from Unilever for its consumer drug business and will continue with its original plan to spin it off as a separate company.
The spinoff will let Glaxo better focus on its main prescription drug and vaccine operations. We… Read More

Expect these recent spinoffs to recover

New spinoffs often struggle for a period, partly because investors tend to dump their new shares. We think that’s why Kyndryl and Viatris are down since they became separate companies. Still, we believe both will eventually move higher, and we see each of them as… Read More

Booster shots good news for Pfizer

PFIZER INC. $49 is a buy. The company (New York symbol PFE; Income-Growth Dividend Payer Portfolio, Manufacturing sector; Shares outstanding: 5.6 billion; Market cap: $274.4 billion; Dividend yield: 3.3%; Dividend Sustainability Rating: Highest; www.pfizer.com) is one of the world’s largest makers of prescription drugs. Its top-selling brands include Eliquis… Read More

Danaher up 280% following spinoffs

Danaher is a great example of how a company can unlock value for shareholders with spinoffs. Since 2016, the conglomerate has completed two separate spinoffs. In that time, the stock has jumped over 280% compared to just 115% for the S&P 500 Index.
More spinoffs are… Read More